Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,787.00+5.07%ETH$2,431.65+7.47%GOLD$4,134.30+1.51%OIL$87.17-1.08%
Smart Investors Daily
SID Premium
SH

OTC · SHTDY

Sinopharm Group Co. Ltd.

Healthcare · Medical - Distribution

$10.75

Up+$0.17 (+1.61%)

Updated Nov 5, 2026, 5:00 AM

SID Score

4.5/10

Composite research score

Smart Money

46/100

Neutral

Market cap
8.07B
P/E ratio
8.43
Dividend yield
4.38%
52-week range
$9.00 – $14.87
Volume
178.15K
Avg. volume
76.73K

Price performance · SHTDY

SHTDY price history

1M range · 0 trading sessions · Daily adjusted prices

SHTDY does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest SHTDY news

The latest Smart Investors Daily articles mentioning SHTDY.

Stock researchCompany · Overview

SHTDY research

Overview

Company profile and research snapshot.

Company profile

SINOPHARM GRP CO UNSP/ADR

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 27, 2026

Sinopharm Group (SEHK:1099) Stock Can Q3 Earnings Turn Revenue Into Profit

Sinopharm Group came into this Q3 2026 earnings release carrying a heavy value label, with the stock on a P/E of about 6x and trading roughly 80% below one analyst fair value estimate, yet priced for caution rather than enthusiasm. The immediate verdict from the market was muted, with the share price at HK$16.30 and only modest gains over the past month, even as quarterly basic earnings per share printed at ¥3.14 and net income from ongoing operations reached ¥1.91b. The real story is a...

Yahoo · Oct 26, 2026

Sinopharm Group (SEHK:1099) Stock Looks Discounted As Shares Fell 19% YTD

Sinopharm Group shares have fallen 19.3% year to date, even as the business continues to generate earnings that investors use as a reference point for value. That slide raises a straightforward question for anyone looking at the stock today: does the current Hong Kong dollar price still line up with what the group earns? The year to date decline of 19.3% puts the focus on whether the recent share price level fairly reflects Sinopharm Group's earnings power. The group relies on steady...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By